Last reviewed · How we verify
APL-101
At a glance
| Generic name | APL-101 |
|---|---|
| Also known as | Bozitinib, Vebreltinib, bozitinib, vebreltinib, CBT-501 |
| Sponsor | Apollomics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (PHASE2)
- A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants (PHASE1)
- APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APL-101 CI brief — competitive landscape report
- APL-101 updates RSS · CI watch RSS
- Apollomics Inc. portfolio CI